Neurocrine Biosciences stock
Price history
+15.12% over the period1 year: from $143.56 (November 17, 2025) to $165.27 (November 17, 2026), +15.12%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $165.27 |
| October 30, 2026 | $146.10 |
| September 30, 2026 | $141.84 |
| August 31, 2026 | $154.03 |
| July 31, 2026 | $166.80 |
| June 30, 2026 | $168.54 |
| May 29, 2026 | $158.30 |
| April 30, 2026 | $131.67 |
| March 31, 2026 | $131.74 |
| February 27, 2026 | $132.25 |
| January 30, 2026 | $136.06 |
| December 31, 2025 | $141.83 |
| November 28, 2025 | $152.16 |
| November 17, 2025 | $143.56 |
At a glance
The company
Discover and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders
Latest results
Quarter to September 30, 2026 · EPS $3.29 (estimate $1.91)
TickerLandia's take on Neurocrine Biosciences
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 35 vs a median of 53 over its last 7 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 25 vs 25 (+0%) in a group of 9.
- Strong point: Growth (77/100 in its group). Weak point: Earnings stability (43/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.85% from the 52-week high
Analysts · 28 analysts
Average target$208.54+25.69% vs. price
Buy 24 · Hold 4 · Sell 0 · Strong buy
TickerLandia Fingerprint: Neurocrine Biosciences
Compared with similar companies: high growth, high financial strength, and high profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage48
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 24.5 44 Forward P/E 13.4 16 EV/EBITDA 15.4 50 Price/book 4.32 62 Price/sales 4.52 69 Profitabilityhigh71
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 64.7% 43 Net margin 19.0% 70 Operating margin 26.6% 70 ROE 20.4% 83 ROA 12.5% 88 Earnings stabilityaverage43
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.1% 22 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh77
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +41.20% 88 Earnings growth (year over year) −3.90% 49 Average revenue growth (3 years) +24.32% 93 Financial strengthhigh73
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.12 76 Current ratio 2.04 49 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.36 74 Interest coverage 308.0 91 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong66
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +12.16% 78 Relative strength (6 months) +4.62% 52 1-year return +15.58% 55 Distance from 200-day average +11.23% 78 Riskaverage52
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 27.2% 45 Volatility (60 days) 37.8% 58 Beta (1 year) 0.71 52
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Neurocrine Biosciences is cheaper than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Neurocrine Biosciences's P/E today is 35.4, below the median of its last 7 fiscal years (53.3; between 23.0 and 275.6 from 2019 to 2025). Neurocrine Biosciences's P/E (trailing 12 months): 24.5, in line with the median of a group of 9 similar companies (24.5).
Compared with 9 similar companies
| Metric | Neurocrine Biosciences | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 24.5 | Middle | |
| Forward P/E | 13.4 | Low | |
| Operating margin | 26.6% | Middle | |
| ROE | 20.4% | High | |
| Debt/equity | 0.12 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Neurocrine Biosciences. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.12B
Latest quarter · Q3 2026
Net income
$206.5M
Latest quarter · Q3 2026
Quarterly net margin
18.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $16.73B
- P/E
- 24.5
- EPS
- $6.74
- Volume
- 1.31M
- Daily trading
- €209.11M
- Dividend yield
- 0.00%
- Last ex-dividend on December 29, 1995
How Neurocrine Biosciences is changing
All resultsRevenue grew 22.3% a year on average over the last 5 years
Operating margin rose from 16.7% to 21.6%
Profits turn into cash: free cash flow equal to 156% of net income
Returns
Neurocrine Biosciences returns
$1,000 invested in Neurocrine Biosciences 5 years ago, on November 17, 2021, would be worth $1,845 today: +84.45% in total, +13.03% per year. This is the price return only: dividends are excluded.
| Period | Neurocrine Biosciences | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +20.65% | −3.17% | $1,207 |
| 6 months | +4.73% | +0.11% | $1,047 |
| Year to date | +16.53% | +8.34% | $1,165 |
| 1 year | +15.12% | +11.15% | $1,151 |
| 3 years | +51.71% | +64.30% | $1,517 |
| 5 years | +84.45% | +58.18% | $1,845 |
| 10 years | +216.19% | +239.10% | $3,162 |
Over the last 6 months it has done better than 31% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Neurocrine Biosciences: technical analysis
Neurocrine Biosciences shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 10.6% below its all-time closing high ($185.50, July 30, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +11.23%
Support and resistance
Price areas where Neurocrine Biosciences has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$169.29+2.03%2 touches, last on July 16, 2026
- Last price$165.92
- Support$161.00−2.97%3 touches, last on September 2, 2026
- Support$153.42−7.54%4 touches, last on August 31, 2026
- Support$147.85−10.89%2 touches, last on October 5, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.71
- Volatility (60 sessions, annualised)
- 37.8%
- Largest fall in the last year
- −27.15%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Neurocrine Biosciences: seasonality
Average monthly price change over 31 years
Over the last 31 years, the strongest month for Neurocrine Biosciences has been January: +6.41% on average, positive in 15 years out of 30. The weakest has been February: −1.54% on average, positive in 9 years out of 30. November, the current month, has been positive in 18 years out of 30 (+3.94% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +6.41% | +1.01% | 15 of 30 |
| February | −1.54% | −2.90% | 9 of 30 |
| March | −0.88% | −1.32% | 12 of 30 |
| April | −1.21% | −2.73% | 10 of 30 |
| May | +5.40% | +7.24% | 18 of 30 |
| June | +2.10% | +1.67% | 17 of 31 |
| July | −0.21% | −0.93% | 15 of 31 |
| August | +1.95% | +1.52% | 16 of 31 |
| September | +2.37% | +0.56% | 17 of 31 |
| October | +2.98% | +2.61% | 18 of 31 |
| November | +3.94% | +4.30% | 18 of 30 |
| December | +4.01% | +3.07% | 19 of 30 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Neurocrine Biosciences and its competitors
Neurocrine Biosciences sells its medicines mainly to patients with neurological and psychiatric disorders, and to patients with endocrine and immunological conditions, in the United States and in other markets outside the country. Its marketed products include INGREZZA, for tardive dyskinesia and chorea linked to Huntington's disease, Orilissa and Oriahnn for gynecological conditions, and CRENESSITY for congenital adrenal hyperplasia, alongside ALKINDI and Efmody. Its pipeline in clinical development targets movement disorders, major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy and obesity.
- Headquarters
- San Diego, United States
- Employees
- 2,500
- Founded
- 1992
- Chief executive
- Kyle Gano
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Neurocrine BiosciencesNBIX | $16.73B | 26.6% | 24.5 | +4.73% |
| ViatrisVTRS | $23.58B | — | — | +24.09% |
| United TherapeuticsUTHR | $25.04B | 39.4% | 22.2 | +2.73% |
| ZoetisZTS | $33.92B | 37.9% | 14.1 | +12.48% |
| Teva Pharmaceutical IndustriesTEVA | $49.67B | 19.8% | 99.0 | +24.29% |
| Hims & Hers HealthHIMS | $4.13B | -6.4% | — | −29.94% |
Same industry or related industries, similar size. Compare Neurocrine Biosciences with its competitors · Full profile
